BDBM148362 US10017516, Compound 29::US9682983, 29

SMILES C(CN1CCCCC1)Oc1ccc(cn1)-c1cnc2c(cnn2c1)-c1cccc2ncccc12

InChI Key InChIKey=AXHZUYXKPFPWMO-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 148362   

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 127nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetActivin receptor type-1(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 127nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 591nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetSerine/threonine-protein kinase receptor R3(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 591nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 6.89E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1B(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 6.89E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 7.59E+3nMpH: 7.5Assay Description:Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against human ALK1-6 enzymes (ALK1: Life Technologies, ALK2-6...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2018
Entry Details
US Patent

TargetBone morphogenetic protein receptor type-1A(Human)
The Brigham and Women'S Hospital

US Patent
LigandPNGBDBM148362(US9682983, 29 | US10017516, Compound 29)
Affinity DataIC50: 7.59E+3nMAssay Description:Compounds were assessed in ALK1-6 enzymatic assays. Specifically, compounds were assayed using LANCE Ultra ULight technology (Perkin Elmer) against h...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/1/2020
Entry Details
US Patent